Profile data is unavailable for this security.
About the company
OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The Company is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. It built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers). The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-7.42m
- Incorporated2018
- Employees4.00
- LocationOS Therapies Inc15825 Shady Grove Road, Suite 135ROCKVILLE 20850United StatesUSA
- Phone+1 (410) 297-7793
- Fax+1 (302) 655-5049
- Websitehttps://ostherapies.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elevation Oncology Inc | 0.00 | -41.95m | 35.67m | 29.00 | -- | 0.5144 | -- | -- | -0.807 | -0.807 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -40.67 | -- | -43.53 | -- | -- | -- | -- | -- | -- | -375.06 | 0.309 | -- | -- | -- | 51.93 | -- | -- | -- |
| Lumos Pharma Inc | 2.21m | -34.92m | 37.28m | 30.00 | -- | 7.59 | -- | 16.91 | -4.29 | -4.29 | 0.2705 | 0.5682 | 0.0676 | -- | 12.75 | 66,818.18 | -107.08 | -29.78 | -132.78 | -32.32 | -- | -- | -1,583.49 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -27.95m | 37.48m | 41.00 | -- | -- | -- | -- | -5.61 | -5.61 | 0.00 | -1.10 | 0.00 | -- | -- | 0.00 | -208.29 | -- | -2,279.15 | -- | -- | -- | -- | -- | -- | -28.13 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -107.49m | 37.70m | 70.00 | -- | 0.3947 | -- | -- | -2.78 | -2.78 | 0.00 | 2.74 | 0.00 | -- | -- | 0.00 | -69.76 | -46.30 | -77.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.92m | 37.86m | 2.00 | -- | 19.94 | -- | -- | -0.306 | -0.306 | 0.00 | 0.0732 | 0.00 | -- | -- | 0.00 | -137.58 | -- | -154.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.09 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -33.38m | 38.12m | 15.00 | -- | -- | -- | -- | -1.12 | -1.12 | 0.00 | -0.2985 | 0.00 | -- | -- | 0.00 | -512.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| OS Therapies Inc | 0.00 | -7.42m | 39.13m | 4.00 | -- | -- | -- | -- | -0.3566 | -0.3566 | 0.00 | -0.0334 | 0.00 | -- | -- | 0.00 | -559.23 | -- | -- | -- | -- | -- | -- | -- | -- | -2.13 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
| Xilio Therapeutics Inc | 4.62m | -62.80m | 39.21m | 73.00 | -- | 1.87 | -- | 8.49 | -1.72 | -1.72 | 0.1046 | 0.4771 | 0.0606 | -- | -- | 63,287.67 | -82.36 | -- | -128.76 | -- | -- | -- | -1,359.37 | -- | -- | -320.73 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| FibroGen Inc | 180.01m | -121.79m | 39.70m | 486.00 | -- | -- | -- | 0.2205 | -1.23 | -1.23 | 1.81 | -2.42 | 0.4967 | 1.29 | 7.49 | 370,399.20 | -34.51 | -30.62 | -103.81 | -42.31 | 76.87 | 93.52 | -69.48 | -119.08 | 1.16 | -7.70 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Exicure Inc | 500.00k | -4.01m | 39.93m | 6.00 | -- | 25.84 | -- | 79.85 | -2.26 | -2.26 | 0.282 | 0.7112 | 0.0424 | -- | 0.4852 | 83,333.34 | -33.98 | -41.52 | -45.26 | -55.78 | -- | -- | -801.40 | -290.95 | -- | -- | 0.00 | -- | -100.00 | -- | -555.07 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -60.70m | 40.04m | 41.00 | -- | 0.4565 | -- | -- | -2.04 | -2.04 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -48.27 | -- | -53.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -30.55m | 41.10m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.5068 | 0.00 | -- | -- | 0.00 | -109.80 | -118.12 | -297.32 | -199.23 | -- | -- | -- | -890,554.10 | -- | -7.38 | 2.05 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 42.06m | 37.00 | -- | 0.9813 | -- | 5.69 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Rallybio Corp | 598.00k | -66.97m | 42.32m | 25.00 | -- | 0.5976 | -- | 70.76 | -1.59 | -1.59 | 0.0141 | 1.71 | 0.0056 | -- | -- | 13,906.98 | -63.12 | -- | -68.83 | -- | -- | -- | -11,199.50 | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 30 Sep 2024 | 60.44k | 0.29% |
| CM Management LLCas of 30 Sep 2024 | 50.00k | 0.24% |
| Delta Investment Management LLCas of 30 Sep 2024 | 18.08k | 0.09% |
| HRT Financial LP (US)as of 30 Sep 2024 | 17.58k | 0.08% |
| UBS Securities LLCas of 30 Sep 2024 | 3.81k | 0.02% |
| Armstrong Advisory Group, Inc.as of 30 Sep 2024 | 100.00 | 0.00% |
